The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: NICE

Bailout Update: New UK Life Sciences Blueprint Aims to Promote Innovation

The UK has a new Life Sciences Blueprint that sets as a goal the creation of an internationally-recognized life sciences cluster.  Here’s the press release and here’s the full report (pdf).  Innovation Pass and Changes at NICE: The Blueprint kicks off an “Innovation Pass” program under which certain novel medicines (criteria TBD) will be available for a 3-year period [...]

Allocating Spending to Support R&D: UK, U.S. and Canadian Approaches

The U.S., Canada and the UK have all acknowledged the central importance of R&D even in these recessionary times.  However, the three national governments have decided to focus their spending on different steps of the R&D equation: Education: UK Takes the Long View British PM Gordon Brown, in a speech this week, identified three priorities: research, education and training, [...]

Wednesday Brain Dump: February 4, 2009

Some good news on the gene therapy front in adenosine deaminase-deficient SCID patients and in rheumatoid arthritis. But mostly bad news on the job front at GSK, AstraZeneca,  Abbott,  GenVec, Patheon, and others. Other good news on the approvals front for Parusgel (despite process concerns), Kapidex, Lamictal, Gelnique and Taxus Liberte. Really small news: Nanomaterials may be heading for [...]

Follow

Get every new post delivered to your Inbox.

Join 84 other followers